Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures

Roughly a week after rejecting Roche's initial buy-out proposal, Genentech announced a generous retention plan to employees who commit to staying through June 2009. Trouble is, the retention plan may not offer much incentive, especially to those ineligible for large bonus packages.

As the biopharma community awaits the next act of the Roche/Genentech Inc. performance to play out, speculation persists over whether the Bay Area icon can retain both its hard-driving culture and the scientific minds that created it given the likelihood that it will soon become a wholly owned subsidiary of the Swiss pharma. [See Deal](See "In Bid For Genentech How High Can Roche Go?" IN VIVO, September 2008 Also see "In Bid For Genentech, How High Can Roche Go?" - In Vivo, 1 September, 2008..)

Genentech recently announced a generous employee retention plan to curb uncertainty among the biotech’s staffers. But off-the-record discussions with Genentech...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.